Aimago Announces FDA Clearance of Its Next-Generation Perfusion Assessment Camera
EasyLDI is Used in Plastic & Reconstructive Surgery, Burns and Wound Care and Makes Perfusion Assessment Non-Invasive, Fast and Effortless, Both Inside & Outside Surgery
(firmenpresse) - LAUSANNE, SWITZERLAND -- (Marketwire) -- 10/03/12 -- Aimago SA, a Swiss medical device company, announces FDA 510(k) clearance of its award-winning, next-generation perfusion camera. The tablet-based Aimago EasyLDI greatly simplifies perfusion assessment; already CE-marked, it is in active use in several leading European plastic & reconstructive surgery, burn care and wound healing centers.
Aimago's EasyLDI provides surgeons and nurses with a highly intuitive, non-invasive, repeatable and user-independent diagnostic imaging tool to objectively identify poorly perfused tissue. This clinically relevant information empowers surgeons to reduce the risk of skin necrosis and delayed healing, thereby leading to better and earlier decision-making for a range of surgical procedures.
Enhanced, Real-Time LDI Brings Numerous Benefits
Aimago's perfusion camera uses the established Laser Doppler Imaging (LDI) technology. The skin is illuminated by laser light, part of which is reflected by moving red blood cells, which, through the Doppler effect, cause a shift in the wavelength of the laser light detected by the LDI camera. Aimago has enhanced this LDI technology to create a fast, intuitive and accurate device, providing tangible benefits:
Michael Friedrich, co-founder and CEO of Aimago, commented, "Our technology and design represent a new paradigm for skin perfusion assessment, with the potential to optimize surgeons' decision-making and greatly facilitate the achievement of successful outcomes, thereby reducing overall cost-of-care. Having attained US clearance, we are confident that EasyLDI will soon become the new reference for perfusion assessment."
More detailed information about EasyLDI, including the technology, product specifications and clinical applications, is available at .
About Aimago
Aimago is a privately held, investor-backed medical device company founded in 2008 as a spin-off from the EPFL (Swiss Federal Institute of Technology in Lausanne) and specializing in perfusion assessment in various clinical settings. Aimago's revolutionary EasyLDI microcirculation camera enjoys patent protection, is already in use at several hospitals in the EU, and is slated for launch in the US in 2012. The company has won several awards, including the CTI MedTech Award 2011 from the Swiss government and the W.A. de Vigier Award for best Swiss start-up. More information is available at .
Contacts:
Aimago SA
Michael Friedrich
Co-Founder and CEO
Parc Scientifique EPFL, PSE-D, 1015 Lausanne, Switzerland
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.10.2012 - 10:30 Uhr
Sprache: Deutsch
News-ID 1157028
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LAUSANNE, SWITZERLAND
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Aimago Announces FDA Clearance of Its Next-Generation Perfusion Assessment Camera
"
steht unter der journalistisch-redaktionellen Verantwortung von
Aimago SA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
